Investigational Therapies1,2

34

TOTAL MOLECULES

Phase III: 8 molecules

Phase II: 9 molecules

Phase I: 32 molecules

Select platforms, tumor types and/or phases below to learn more.

Learn more about Genentech's investigational therapies. Click to expand.

Tumor types
Development platforms
Phases

The compounds and their uses mentioned on this website are investigational and have not been approved by the US Food and Drug Administration. Efficacy and safety have not been established. The information presented should not be construed as a recommendation for use. The relevance of findings in preclinical studies to humans is currently being evaluated.

Phase III

  • Hematology
  • Small Molecules

Ipatasertib
(AKT inhibitor)

(GDC-0068, RG7440)a

Find out more about how ipatasertib, an Akt inhibitor, is proposed to work.

  • Breast
  • Gastrointestinal
  • Genitourinary
  • Small Molecules
  • Hematology
  • Antibody Drug Conjugates

Atezolizumab
(anti-PDL1 MAb)

(RG7446)

 

  • Breast
  • Gastrointestinal
  • Genitourinary
  • Gynecologic
  • Head and Neck
  • Hematology
  • Melanoma
  • Solid Tumor
  • Monoclonal Antibodies

Bevacizumab

(anti-VEGF MAb)

 

  • Gastrointestinal
  • Monoclonal Antibodies

Cobimetinib
(MEK inhibitor)

(RG7421)c

 

  • Breast
  • Genitourinary
  • Gastrointestinal
  • Hematology
  • Solid Tumor
  • Small Molecules

Venetoclax
(BCL-2 inhibitor)

(ABT-199/GDC-0199, RG7601)d

 

  • Hematology
  • Small Molecules

Phase II

  • Hematology
  • Small Molecules

Ipatasertib
(AKT inhibitor)

(GDC-0068, RG7440)a

Find out more about how ipatasertib, an Akt inhibitor, is proposed to work.

  • Breast
  • Gastrointestinal
  • Genitourinary
  • Small Molecules
  • Hematology
  • Antibody Drug Conjugates

Atezolizumab
(anti-PDL1 MAb)

(RG7446)

 

  • Breast
  • Gastrointestinal
  • Genitourinary
  • Head and Neck
  • Hematology
  • Monoclonal Antibodies

Cobimetinib
(MEK inhibitor)

(RG7421)c

 

  • Breast
  • Genitourinary
  • Gastrointestinal
  • Head and Neck
  • Hematology
  • Solid Tumor
  • Small Molecules

Codrituzumab
(glypican-3 MAb)

(GC33, RG7686)e

 

  • Gastrointestinal
  • Monoclonal Antibodies

Entrectinib

(NTRK/ROS1 inhibitor)

(RXDX-101, RG6268)f

 

  • Lung
  • Pan Tumor
  • Small Molecules

Venetoclax
(BCL-2 inhibitor)

(ABT-199/GDC-0199, RG7601)d

 

  • Hematology
  • Small Molecules

Phase I

  • Solid Tumor
  • T-cell Bispecific Antibodies
  • Hematology
  • Small Molecules

Ipatasertib
(AKT inhibitor)

(GDC-0068, RG7440)a

Find out more about how ipatasertib, an Akt inhibitor, is proposed to work.

  • Breast
  • Gastrointestinal
  • Genitourinary
  • Small Molecules
  • Hematology
  • T-cell Bispecific Antibodies
  • Hematology
  • Antibody Drug Conjugates

Antibody-drug conjugate

(RG6109)

 

  • Hematology
  • Antibody Drug Conjugates

Antibody-drug conjugate

(RG6148)

 

  • Breast
  • Antibody Drug Conjugates

Anti-MUC16 TDC

(RG7882)b

 

  • Gastrointestinal
  • Gynecologic
  • Antibody Drug Conjugates

Atezolizumab
(anti-PDL1 MAb)

(RG7446)

 

  • Breast
  • Gastrointestinal
  • Genitourinary
  • Gynecologic
  • Head and Neck
  • Hematology
  • Melanoma
  • Solid Tumor
  • Monoclonal Antibodies

BET inhibitor

(TEN-010, RG6146)g

 

  • Breast
  • Gynecologic
  • Hematology
  • Solid Tumor
  • Small Molecules

CD20 TCB

(RG6026)

 

  • Hematology
  • T-cell Bispecific Antibodies

Cergutuzumab amunaleukin
(CEA-IL2v)

(RG7813)

 

  • Solid Tumor
  • Monoclonal Antibodies

ChK1 inhibitor

(GDC-0575, RG7741)a

 

  • Solid Tumor
  • Small Molecules

Cobimetinib
(MEK inhibitor)

(RG7421)c

 

  • Breast
  • Genitourinary
  • Head and Neck
  • Gastrointestinal
  • Hematology
  • Small Molecules

Codrituzumab
(glypican-3 MAb)

(GC33, RG7686)e

 

  • Gastrointestinal
  • Monoclonal Antibodies

Emactuzumab
(CSF-1R MAb)

(RG7155)

 

  • Solid Tumor
  • Monoclonal Antibodies

Entrectinib

(NTRK/ROS1 inhibitor)

(RXDX-101, RG6268)f

 

  • Lung
  • Pan Tumor
  • Solid Tumor
  • Small Molecules

FAP-DR5 biMAb

(RG7386)

 

  • Solid Tumor
  • Monoclonal Antibodies

FAP-IL2v FP

(RG7461)

 

  • Breast
  • Genitourinary
  • Head and Neck
  • Lung
  • Solid Tumor
  • Monoclonal Antibodies

Glypican-3/CD3 biMAb

(CHU)e

 

  • Solid Tumor
  • Monoclonal Antibodies

Monoclonal antibody

(RG6160)

 

  • Hematology
  • Monoclonal Anitbodies

Monoclonal antibody

(RG6194)

 

  • Solid Tumor
  • Monoclonal Anitbodies

Obinutuzumab

(anti-CD20 MAb)

(RG7159)

 

  • Solid Tumor
  • Monoclonal Antibodies

Pan-RAF inhibitor

(RG6185)

 

  • Solid Tumor
  • Small Molecules

Personalized cancer vaccine

(RG6180)h

 

  • Solid Tumor
  • Personalized Cancer Vaccines

PI3K inhibitor

(GDC-0077, RG6114)

 

  • Breast
  • Solid Tumor
  • Small Molecules

Raf/MEK dual inhibitor

(CHU)e

 

  • Solid Tumor
  • Small Molecules

Selective estrogen receptor degrader

(SERD [3])

(GDC-9545, RG6171)

 

  • Breast
  • Small Molecules

Selicrelumab
(CD40 MAb)

(RG7876)

 

  • Solid Tumor
  • Monoclonal Antibodies

Tiragolumab

(anti-TIGIT)

(MTIG7192A, RG6058)

 

  • Solid Tumor
  • Monoclonal Antibodies

Vanucizumab
(ANG2-VEGF biMAb)

(RG7221)

 

  • Gynecologic
  • Solid Tumor
  • Monoclonal Antibodies

Venetoclax
(BCL-2 inhibitor)

(ABT-199/GDC-0199, RG7601)d

 

  • Hematology
  • Small Molecules

aDeveloped in collaboration with Array BioPharma. bDeveloped in collaboration with Seattle Genetics. cDeveloped in collaboration with Exelixis. dJoint project with AbbVie. eDeveloped in collaboration with Chugai. fIgnyta Inc acquisition. gTensha acquisition. hDeveloped in collaboration with BioNTech.

References

  1. Roche first-quarter results 2018 presentation. www.roche.com/dam/jcr:6f4ad9a6-3ece-4184-aff4-ea6cd4a4b7ac/en/irp180426.pdf. Accessed April 26, 2018.
  2. US National Institutes of Health. ClinicalTrials.gov. https://clinicaltrials.gov. Accessed May 7, 2018.